• Mi Re-Unir
    Búsqueda Avanzada
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Ver ítem 
    •   Inicio
    • RESULTADOS DE INVESTIGACIÓN
    • Artículos Científicos WOS y SCOPUS
    • Ver ítem
    •   Inicio
    • RESULTADOS DE INVESTIGACIÓN
    • Artículos Científicos WOS y SCOPUS
    • Ver ítem

    Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions

    Autor: 
    Mendoza, Carmen de
    Lozano, A. B.
    Caballero, Estrella
    Cabezas, Teresa
    Ramos, José M.
    Soriano, Vicente (1)
    Spanish HIV-2 Network
    Fecha: 
    01/2020
    Palabra clave: 
    HIV-2; antiretroviral therapy; drug resistance; integrase inhibitors; dual HIV infection; HIV superinfection; Scopus; JCR
    Tipo de Ítem: 
    Articulo Revista Indexada
    URI: 
    https://reunir.unir.net/handle/123456789/10256
    DOI: 
    https://doi.org/10.24875/AIDSRev.M20000029
    Dirección web: 
    http://www.aidsreviews.com/resumen.php?id=1520
    Resumen:
    Human immunodeficiency virus type 2 (HIV-2) was isolated in AIDS patients in 1986. Around 1-2 million people are infected worldwide. The virus is less transmissible than HIV-1, being sexual contacts the most frequent route of acquisition. In the absence of antiretroviral therapy, most HIV-2 carriers will develop AIDS; however, it takes longer than in HIV-1 infection. There is no global pandemic caused by HIV-2, as the virus is largely confined to West Africa. Due to historical ties, HIV-2 is also prevalent in Portugal and its former colonies in Brazil, India, Mozambique, and Angola. Other European countries with hundreds to thousands of HIV-2 infections are France, Belgium, and Spain. A few hundred have been reported in North America, mostly in West African foreigners. Globally, HIV-2 infections are steadily declining. Although CD4 declines occur more slowly in HIV-2 than in HIV-1 patients, the CD4 recovery with antiretroviral treatment is smaller in the former. HIV-2 is naturally resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and some protease inhibitors. In contrast, HIV-2 is susceptible to all NRTIs and integrase inhibitors. Drug resistance in HIV-2 may develop earlier than in HIV-1 and select for mutations at distinct sites. Misdiagnosis of HIV-2 in patients wrongly considered as HIV-1 positive or in those dually infected may result in treatment failures with undetectable HIV-1RNA. Given the relatively large number of West Africans migrated to the European Union and North America, HIV-2 infection either alone or as coinfection with HIV-1 should be excluded at least once in all HIV-seroreactive persons. This should be stressed in the face of atypical HIV serological profiles, immunovirological disconnect (CD4 cell count loss despite undetectable HIV-1 viremia), and/or high epidemiological risks (birth in or sex partners from HIV-2 endemic regions). Superinfection with any HIV variant may occur in persons infected with the other, since there is no cross-protection. Thus, earlier antiretroviral therapy is warranted for either HIV-1 or HIV-2, given that it would protect from each other superinfection in persons at risk.
    Mostrar el registro completo del ítem
    Este ítem aparece en la(s) siguiente(s) colección(es)
    • Artículos Científicos WOS y SCOPUS

    Estadísticas de uso

    Año
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    Vistas
    0
    0
    0
    0
    0
    0
    0
    0
    161
    1
    Descargas
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0

    Ítems relacionados

    Mostrando ítems relacionados por Título, autor o materia.

    • Treatment outcome in dually HIV-1 and HIV-2 coinfected patients living in Spain 

      Requena, S.; Caballero, Estrella; Lozano, A. B.; Ríos-Villegas, María; Benito, Rafael; Rojo, Silvia; Cabezas, Teresa; Macià, María; Nieto, María del; Soriano, Vicente (1); Mendoza, Carmen de (AIDS, 15/11/2019)
      Background: Whereas HIV-1 has spread globally, HIV-2 is mainly found in West Africa where dual HIV-1/HIV-2 coinfection is nowadays uncommon. Herein, we report the rate, main characteristics, and treatment outcomes of all ...
    • Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain 

      Mendoza, Carmen de; Pirón, María; González, Rocío; Jiménez, Ana; Caballero, Estrella; Roc, Lourdes; Benito, Rafael; Soriano, Vicente (1); Corral, Octavio Jorge (1); ...et al.; Gómez-Gallego, Felix (1) (Open Forum Infectious Diseases, 02/2019)
      Background. Although only 8%-10% of persons infected with human T-cell leukemia virus type 1 (HTLV-1) may develop virus-associated diseases lifelong, misdiagnosis of asymptomatic infected carriers frequently leads to late ...
    • HIV co-infection in HTLV-1 carriers in Spain 

      Mendoza, Carmen de; Caballero, Estrella; Aguilera, Antonio; Benito, Rafael; Maciá, Dolores; García-Costa, Juan; Soriano, Vicente (1); Corral, Octavio Jorge (1); Gómez-Gallego, Felix (1); ...et al.; Morano, Luis (Virus Research, 06/2019)
      Background: Human retroviruses HIV and HTLV share transmission routes. HIV widely spread in Spain during the 80 s through injection drug use and sex, and nowadays HIV rates in Spain account for one of the largest in Europe. ...

    Mi cuenta

    AccederRegistrar

    ¿necesitas ayuda?

    Manual de UsuarioAutorización TFG-M

    Listar

    todo Re-UnirComunidades y coleccionesPor fecha de publicaciónAutoresTítulosPalabras claveTipo documentoTipo de accesoEsta colecciónPor fecha de publicaciónAutoresTítulosPalabras claveTipo documentoTipo de acceso






    Aviso Legal Política de Privacidad Política de Cookies Cláusulas legales RGPD
    © UNIR - Universidad Internacional de La Rioja
     
    Aviso Legal Política de Privacidad Política de Cookies Cláusulas legales RGPD
    © UNIR - Universidad Internacional de La Rioja